Clinical Factors Influencing Phenotype of HCMV-Specific CD8+ T Cells and HCMV-Induced Interferon-Gamma Production after Allogeneic Stem Cells Transplantation

Table 1

Clinical characteristics of the study population.

Characteristics	Data
Patients (number)	26
Recipient age (years): mean (SD)	40 (13.5)
Donor age (years): mean (SD)	40 (15)
Recipient sex, male/female, (𝑛, (%))	15 (57.7)/11 (42.3)
Donor sex, male/female (𝑛, (%))	20 (76.9)/6 (23.1)
Disease (𝑛, (%))
AML	5 (19.2)
ALL	2 (7.6)
CML	3 (11.5)
Non-Hodgkin’s lymphoma	4 (15.3)
MM	4 (15.3)
Aplasia	2 (7.6)
MDS	3 (11.5)
PNH	3 (11.5)
Conditioning regimen (𝑛, (%))
NMA	13 (50)
MA	13 (50)
Stem cell source (𝑛, (%))
Bone marrow	12 (46.1)
Peripheral blood	14 (53.8)
Pretransplant HCMV donor serostatus/recipient (𝑛, (%))
D+/R+	14 (53.8)
D−/R+	10 (38.4)
D−/R−	2 (7.7)
HCMV replication after transplant (𝑛, (%))
Yes	15 (57.7)
No	11 (42.3)
HLA matching (𝑛, (%))
Matched related	18 (69.2)
Matched unrelated	6 (23.1)
Mismatched unrelated	2 (7.7)
GVHD (𝑛, (%))
Yes	11 (42.3)
No	15 (57.7)
Corticosteroids (𝑛, (%))
Yes	18 (69.2)
No	8 (30.8)
Frequency of CD8+ T cells (mean, SD)	35.1 (14.8)
Frequency of HCMV-specific CD8+ T cells (mean, SD)	1.4 (2.1)
Frequency of HCMV-specific CD8+ T cells naive (mean, SD)	6.7 (11.3)
Frequency of HCMV-specific CD8+ T cells CD28+ (mean, SD)	30 (23.2)

AML: acute myeloid leukemia; ALL: acute lymphatic leukemia; CML: chronic myeloid leukemia; MM: multiple myeloma; MDS: myelodysplastic syndrome; PNH: paroxysmal nocturnal hemoglobinuria; NMA: non-myeloablative; MA: myeloablative. D: donor; R: recipient; HCMV: human cytomegalovirus; GVHD: graft-versus-host disease. Naive cells are CD45RA+CCR7+.